Molecular Cancer Therapeutics | American Association for Cancer Research

Skip Nav Destination

Current Issue

Volume 21,

Issue 5

1 May 2022

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

6.261

SUBMIT TO JOURNAL

Featured Articles

Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

O’Brien et al.

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

Javaid et al.

Proteolytic pan-RAS cleavage leads to tumor regression in patient-derived pancreatic cancer xenografts

Vidimar et al.

Trending - Altmetric

Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers

Last mentioned on Monday May 16 2022

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells

Last mentioned on Monday May 16 2022

The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms

Last mentioned on Sunday May 15 2022

Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts

Last mentioned on Sunday May 15 2022

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

Last mentioned on Sunday May 15 2022

Latest
Most Read
Most Cited

Variable mutation expression in human cancers: A 'hide-and-seek' mechanism linked to differential MHC-I presentation dynamics

Peptide PDHPS1 inhibits ovarian cancer growth through disrupting YAP signaling

Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles

Overcoming Resistance to Anti-nectin-4 Antibody-Drug Conjugate

Tweets by MCT_AACR

About the Journal

Editor-in-Chief

Impact Factor

Featured Articles

Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

Proteolytic pan-RAS cleavage leads to tumor regression in patient-derived pancreatic cancer xenografts

Trending - Altmetric

AACR Journals

This Feature Is Available To Subscribers Only